Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
Purpose
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Condition
- Type 1 Diabetes
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Adults ≥18 years of age - Clinical diagnosis of T1D - GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week - Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study - Willing and able to provide informed consent
Exclusion Criteria
- No exclusion criteria other than those not meeting inclusion criteria above
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Prospective
Recruiting Locations
Hoag Memorial Hospital
Newport Beach, California 92663
Newport Beach, California 92663
Northwestern University
Chicago, Illinois 60611
Chicago, Illinois 60611
Maine Health Research Institute
Portland, Maine 04102
Portland, Maine 04102
Harvard Medical School
Boston, Massachusetts 02115
Boston, Massachusetts 02115
More Details
- Status
- Recruiting
- Sponsor
- Indiana University